CD274 and non-small cell lung carcinoma: This conclusion was different to a recent cost-effectiveness analysis that combined network-meta analysis conducted in NSCLC patients with PD-L1>50%, which indicated that the first-line cemiplimab monotherapy was a cost-effective option compared with pembrolizumab, while atezolizumab was a minor alternative against cemiplimab or pembrolizumab (28).